MeSH tree: D27.505.696.422.125
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—a type of medication that mimics the GLP-1 hormone—to lower blood sugar and support weight loss. Some research ...
15 hours ago
0
3
For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering ...
Jul 16, 2026
0
4
The popularity of GLP-1 drugs has created a new generation of body contouring patients and a new set of challenges for plastic surgeons.
Jul 16, 2026
0
5
Drugs commonly used for weight loss, known as GLP-1 receptor agonists, have been found to reduce the key symptoms of binge eating disorder in a new review of evidence led by University College London (UCL) researchers.
Jul 15, 2026
0
5
Public interest in obesity medication has risen 25-fold since the launch of GLP-1 receptor agonist drugs, new research presented at the International Congress on Obesity (ICO2026) in Mexico City, Mexico, hosted by the World ...
Jul 15, 2026
0
19
As a Gen Xer who lived through the "heroin chic" years, when skeletal models were celebrated for jutting bones and sallow skin, the recent popularity of the #Y2KSkinny trend fills me with dread.
Jul 14, 2026
0
2
In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts about GLP-1 drugs and cancer. The headlines were everywhere—from NPR and The Washington Post to Substack ...
Jul 13, 2026
0
5
For many people living with obesity, newer weight-loss medicines such as Wegovy and Mounjaro have been transformative. These drugs are often grouped under the label GLP-1 medicines because they mimic hormones released after ...
Jul 10, 2026
0
6
The share of U.S. adults taking GLP-1 medications to lose weight has reached a record 11%.
Jul 9, 2026
0
14
Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding the use of obesity drugs for weight loss treatment. The statement, which is published in The Lancet Diabetes ...
Jul 9, 2026
0
5
